Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
Alvotech (NASDAQ: ALVO) said it closed its underwritten public offering on June 17, 2026, selling 26,066,667 ordinary shares at $3.75 each, including full exercise of the underwriters’ option for 3,400,000 additional shares. Gross proceeds to the company were about $98 million. A concurrent $67 million private placement of 17,826,666 shares is expected to close around June 25, bringing total gross proceeds to about $165 million.
How this was made
The 30-second read
Why it matters
The transaction provides ~$165M gross funding for biosimilar development, working capital, and potential corporate actions, but increases share count (43.9M new shares delivered post-closing of the concurrent placement).
Market read
Deal terms (price, share count, gross proceeds) are concrete and can drive near-term trading via dilution expectations and funding-runway reassessment.
What to watch
Watch for the private placement closing timing (June 25) and any subsequent use-of-proceeds updates; dilution impact depends on net proceeds after fees and how quickly management converts funding into measurable pipeline progress.
Background
Alvotech announced and has now closed an underwritten public offering, alongside a concurrent EEA-qualified private placement exempt from US registration requirements.
Ticker impact
Alvotech closed a $98M underwritten public offering at $3.75/share and expects ~$67M from a concurrent private placement, totaling ~$165M gross proceeds.
Near-term pressure possible from dilution expectations, partially offset by funding clarity; direction likely depends on whether investors view proceeds as sufficient for pipeline milestones.
The article provides hard deal terms (share count, price, gross proceeds) but no incremental guidance or pipeline readout; typical market reaction is dilution-aware unless proceeds materially de-risk upcoming catalysts.
Market effects
Biosimilar peers may face read-across on financing conditions and dilution appetite for development-stage biotech.
Limited direct regional impact; deal is US-listed with EEA-qualified investor private placement.
Global biosimilar funding narrative may influence investor risk appetite for non-innovator pharma development programs.
Counterpoint
If the proceeds are earmarked for specific de-risking milestones (clinical/pre-commercialization and IP enforcement), the market may re-rate the stock despite dilution.
Key entities
- companyAlvotech
NASDAQ-listed biosimilar developer that closed a $98M public offering and expects ~$67M from a concurrent private placement.
- bankBofA Securities
Joint book-running manager for the offering.
- bankJefferies
Joint book-running manager for the offering.
- bankEvercore ISI
Joint book-running manager for the offering.
